Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Atrial Fibrillation

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

J Cardiovasc Med (Hagerstown).

De Caterina R, Kelly P, Monteiro P3, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators

doi: 10.2459/JCM.

Atrial Fibrillation

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: One year follow up of the prospective observational ETNA-AF-Europe study

Eur Heart J Cardiovasc Pharmacother.

de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P, ETNA-AF-Europe investigators

doi: 10.1093/ehjcvp/pvaa079.

Atrial Fibrillation

Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Am Heart J.

Jackson LR 2nd, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.

doi: 10.1016/j.ahj.2020.04.016.

Atrial FibrillationHeart, Artery and Coronary DiseasesMyocardial Infarction

Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study

JAMA Cardiol.

Inohara T, Shrader P, Pieper K, Blanco RG, Thomas L, Singer DE, Freeman JV, Allen LA, Fonarow GC, Gersh B, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Steinberg BA, Peterson ED, Piccini JP

doi: 10.1001/jamacardio.

Atrial Fibrillation

Patient-Reported Outcomes and Patient-Reported Experience of Patients With Atrial Fibrillation in the IMPACT-AF Clinical Trial

J Am Heart Assoc

Humphries B, Cox JL, Parkash R, Thabane L, Foster GA, MacKillop J, Nemis-White J, Hamilton L, Ciaccia A, Choudhri SH, Xie F, IMPACT‐AF Investigators.

doi: 10.1161/JAHA.120.019783

Atrial Fibrillation

Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool

Am Heart J.

Cox JL, Parkash R, Foster GA, Xie F, MacKillop JH, Ciaccia A, Choudhri SH, Hamilton LM, Nemis-White JM, Thabane L, IMPACT-AF Investigators.

doi: 10.1016/j.ahj.2020.02.019.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients

JACC: Clinical Electrophysiology.

Kubo S, Mizutani Y, Meemook K, Nakajima Y, Hussaini A, Kar S

doi: 10.1016/j.jacep.2017.05.006.

COMMENTED

Atrial Fibrillation

Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial

★ 3 Recommended and commented by Prof. Dr Sacha P. Salzberg, Faculty Member

doi: 10.1001/jama.2019.21187.

Atrial Fibrillation

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

Clin Res Cardiol.

Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH

doi: 10.1007/s00392-019-01594-9.

Related content

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: One year follow up of the prospective observational ETNA-AF-Europe study

Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study

Patient-Reported Outcomes and Patient-Reported Experience of Patients With Atrial Fibrillation in the IMPACT-AF Clinical Trial

Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool

Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients

Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial